But one person had a slightly different take: “Our industry believes comparative information on cost is equally important,” said Carmella Bucchino of America's Health Insurance Plans. “If one intervention is marginally better, we still want to know how much more we're paying for that benefit.”
The makeup of the IOM committee was the subject of some controversy. After a group of 20 public interest, patient advocacy, and consumer groups complained in a letter that the panel had only one consumer representative, two more were added.